

At page 1, please replace the heading and paragraph from lines 3-8 with the following header and paragraph:

--Cross Reference to Related Applications

Q' This application is a National Stage Application of PCT International Application No. PCT/US99/08285, filed April 15, 1999, and claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application No. 60/115,516, filed April 15, 1998, now abandoned, incorporated by reference herein in its entirety.

At page 1 of the specification, please replace the paragraph at lines 26-29 with the following paragraph:

Q<sup>2</sup> This application is related to U.S. Patent Application No. 08/734,607, filed October 18, 1996, now U.S. Patent No. 6,210,913; U.S. Provisional Application No. 60/031,665, filed November 21, 1996; U.S. Provisional Application No. 60/042,093, filed March 28, 1997; and, U.S. Patent Application No. 08/975,653, filed November 21, 1997. All of the publications and patent applications that are identified in this specification are hereby incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

At page 19 of the specification, please replace the paragraph at lines 24-31 with the following paragraph:

Q<sup>3</sup>  
The sequence for the murine genomic DNA is not known and has not been published, however part of the amino acid sequence of mouse GP IIIa was available (Cietat et al. (1993) *Biochem et Biophys Res Comm.* 193: 771-778, and Dr Jean-Phillipe Rosa, *Unite INSERM* 348, Paris) and its similarity to human GP IIIa sequence suggested the genomic GP IIIa from humans and mice could be fairly similar. Therefore, several PCR primers were generated towards the mouse GP IIIa sequence in areas which, in the case of human GP IIIa (SEQ ID NO. 1), spanned the two exons known to encode the cytoplasmic domain of GP IIIa ie. exons M and N (Lanza, F. et al. (1990) *J. Biol. Chem.* 265: 18098-18103). These primers were then tested with total

At page 20, please insert the following paragraph starting at line 14:

The amino acid sequence having SEQ ID NO. 1 is as follows:

Q<sup>4</sup>  
SUB 84)  

GPNICTTRGV	SSCQQCLAVS	PMCAWSDEA	LPLGSPRCDL	KENLLKDNCA	PESIEFPVSE	60
ARVLEDRLPS	DKSGDSSQV	TOVSPQRIAL	RLRPDDSKNF	SIQVRQVEDY	PVDIYYLMDL	120
SYSMKDDLWS	IQNLGTKLAT	QMRKLTSNLR	IGFGAFVDKP	VSPYMYISPP	EALENPCYDM	180
KTTCLPMFGY	KHVLTLTDQV	TRFNEEVKKQ	SVSRNRDAPE	GGFDAIMQAT	VCDEKIGWRN	240
DASHLLVFTT	DAKTHIALDG	RLAGIVQPND	GQCHVGSDNH	YSASTTMDYP	SLGLMTEKLS	300
QKNINLIFAV	TENVVNLYQN	YSELIPGTTV	GVLSMDSSNV	LQLIVDAYGK	IRSKVELEVR	360
DLPEELSLSF	NATCLNNEVI	PGLKSCMGLK	IGDTVFSFIE	AKVRGCPQEK	EKSFTIKPVG	420
FKDSLIVQVT	FDCDCACQAA	AEPNSHRCNN	GNGTFECGVC	RCGPGWLGSQ	CECSEEDYRP	480
SQQDECSPRE	GQPVCSQRGE	CLCGQCVCNS	SDFGKITGKY	CECDDFSCVR	YKGEMCSGHG	540
QCSCGDCLCD	SDWTGYCNC	TTRTDTCMSS	NLLCSGRGK	CECGSCVCIQ	PGSYGDTCEK	600
CPTCPDACTF	KKECVECKKF	DRGALHDENT	GNRYCRDEIE	SVKELKDTGK	DAVNCTYKNE	660
DDCVVRFAQY	EDSSGKSILY	VVEEPECPKG	PIILVVLLSV	MGAILLIGLA	ALLIWKLLIT	720
IHDRKEPAKF	EEERARAKWD	TANNPLYKEA	TSTFTNITYR	GT		762

Please insert Sequence Listing pages 1-9 after the Abstract in the specification.

IN THE CLAIMS:

Please amend the claims as follows: